Beyond Achondroplasia

Growing together with Clara

BioMarin at the Wells Fargo 9th Annual Healthcare Conference


Dan Oppenheimer, Group Vice President, Development & Portfolio Strategy – BioMarin Pharmaceutical Inc, presented today at the Wells Fargo research conferences the actual state of art of BioMarin´s drugs under evaluation, including BMN-111.

Has said, BioMarin predicts to have results from the BMN-111 phase 2 on the second quarter of 2015.

BMN-111 is expected to have it´s final dosis between cohort 1) 2.5 microgram/kg and cohort 2) 7.5 microgram/kg.

To listen to the webcast here, (starting at minute 16).


Still a long road to travel.



Leave a Reply

Required fields are marked *.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Translate »